Beksac, M., Corso, A., Richter, J. R., Ballew, N., Jadhav, V., Purser, M., McNamara, S., Sapra, S., Sieverding, M., Wang, Z., Kazeem, G. (2025). Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7536